Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes.

Murakami H, Tanabe J, Tamasawa N, Matsumura K, Yamashita M, Matsuki K, Murakami H, Matsui J, Suda T.

Diabetes Res Clin Pract. 2013 Jan;99(1):30-8. doi: 10.1016/j.diabres.2012.10.022. Epub 2012 Nov 5.

PMID:
23137417
2.

Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus.

Tan HC, Tai ES, Sviridov D, Nestel PJ, Ng C, Chan E, Teo Y, Wai DC.

J Clin Lipidol. 2011 Nov-Dec;5(6):467-73. doi: 10.1016/j.jacl.2011.06.016. Epub 2011 Jun 28.

PMID:
22108150
3.

Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.

Kappelle PJ, de Boer JF, Perton FG, Annema W, de Vries R, Dullaart RP, Tietge UJ.

Eur J Clin Invest. 2012 May;42(5):487-95. doi: 10.1111/j.1365-2362.2011.02604.x. Epub 2011 Sep 28.

PMID:
21955281
4.
6.

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.

Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ.

Circ Res. 2005 Oct 14;97(8):763-71. Epub 2005 Sep 8.

7.

The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome.

Dullaart RP, Kwakernaak AJ, Dallinga-Thie GM.

Atherosclerosis. 2013 Sep;230(1):6-11. doi: 10.1016/j.atherosclerosis.2013.06.019. Epub 2013 Jul 1.

PMID:
23958245
8.

High-density lipoprotein composition and paraoxonase activity in Type I diabetes.

Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS.

Clin Sci (Lond). 2001 Dec;101(6):659-70.

PMID:
11724654
9.

Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux.

Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC.

J Lipid Res. 1995 May;36(5):1058-65.

10.

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.

Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM.

Circulation. 2004 Jun 29;109(25):3215-20. Epub 2004 Jun 14.

11.

Glycemic control and high-density lipoprotein characteristics in adolescents with type 1 diabetes.

Medina-Bravo P, Medina-Urrutia A, Juárez-Rojas JG, Cardoso-Saldaña G, Jorge-Galarza E, Posadas-Sánchez R, Coyote-Estrada N, Nishimura-Meguro E, Posadas-Romero C.

Pediatr Diabetes. 2013 Sep;14(6):399-406. doi: 10.1111/j.1399-5448.2012.00924.x. Epub 2012 Oct 11.

PMID:
23057424
12.

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN.

J Clin Invest. 1998 Apr 15;101(8):1581-90.

13.

Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome.

Kappelle PJ, Bijzet J, Hazenberg BP, Dullaart RP.

Arch Med Res. 2011 Apr;42(3):219-25. doi: 10.1016/j.arcmed.2011.05.002.

PMID:
21722818
14.

Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.

Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlbäck B, Nielsen LB.

J Intern Med. 2009 Sep;266(3):258-67. doi: 10.1111/j.1365-2796.2009.02095.x. Epub 2009 Mar 7.

15.

ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.

Gaidukov L, Viji RI, Yacobson S, Rosenblat M, Aviram M, Tawfik DS.

Biochemistry. 2010 Jan 26;49(3):532-8. doi: 10.1021/bi9013227.

PMID:
20025294
16.

Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic and non-diabetic subjects.

Dullaart RP, Otvos JD, James RW.

Clin Biochem. 2014 Aug;47(12):1022-7. doi: 10.1016/j.clinbiochem.2014.04.013. Epub 2014 Apr 21.

PMID:
24769273
17.

Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.

Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D.

J Diabetes Complications. 2010 Sep-Oct;24(5):325-33. doi: 10.1016/j.jdiacomp.2009.04.001. Epub 2009 Jun 23.

PMID:
19553142
18.

Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I.

Blatter Garin MC, Moren X, James RW.

J Lipid Res. 2006 Mar;47(3):515-20. Epub 2005 Dec 3.

19.

Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease.

Attia N, Nakbi A, Smaoui M, Chaaba R, Moulin P, Hammami S, Hamda KB, Chanussot F, Hammami M.

Tohoku J Exp Med. 2007 Oct;213(2):129-37.

20.

Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy.

Maranghi M, Hiukka A, Badeau R, Sundvall J, Jauhiainen M, Taskinen MR.

Atherosclerosis. 2011 Nov;219(1):259-65. doi: 10.1016/j.atherosclerosis.2011.05.018. Epub 2011 May 25.

PMID:
21696738

Supplemental Content

Support Center